Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

Objective Response Rate Clinical Trial

Official title:
Sequential Low-dose Decitabine Therapy With Novel CAR-T Carrying PD-1/CD28 Chimeric Switch Receptor in Relapsed or Refractory B-cell Lymphoma

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of CD19 PD-1/CD28-CAR-T sequential low-dose decitabine in the treatment of relapse or refractory B cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Objective Response Rate

Clinical Trial Details

NCT number	NCT04850560
Study type	Interventional
Source	Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact	Hui Liu, MD, PhD
Phone	13819198629
Email	sylenliu@zju.edu.cn
Status	Recruiting
Phase	Phase 1
Start date	May 18, 2021
Completion date	May 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05760196` - Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors	Phase 2
Recruiting	`NCT04635956` - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas	Phase 2
Recruiting	`NCT04670978` - Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer	Phase 2
Recruiting	`NCT05310383` - Tislelizumab and Radiotherapy for Recurrent Cervical Cancer	Phase 2
Suspended	`NCT05503108` - Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer	Phase 3
Recruiting	`NCT06125834` - Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy	Phase 2
Recruiting	`NCT03892577` - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Recruiting	`NCT04664244` - Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma	Phase 2